Serum Institute of India Ltd has established itself as the world's largest producer of measles and Diphtheria, Tetanus and Pertussis (DTP) group of vaccines. It is estimated that two out of every three children immunised in the world is vaccinated by a vaccine manufactured by Serum Institute. In fact, their range of products has been used in 140 countries across the globe.
Serum Institute of India was founded in 1966 with the aim of manufacturing life-saving immuno-biologicals, which were in shortage in the country and imported at high prices. Thereafter, several life-saving biologicals were manufactured at prices affordable to the common man and in abundance, with the result that the country was made self-sufficient for tetanus anti-toxin and anti-snake venom serum, followed by DTP group of vaccines and then later on measles, mumps and rubella (MMR) group of vaccines.
Serum Institute of India has recently set up the Serum Bio Pharma Park, India's first biotech special economic zone (SEZ). The Park is adjoining Serum Institute's existing manufacturing unit and is a sector-specific SEZ meant for biotechnology and pharmaceutical products.
Serum Institute of India: Gaining Global Ground
|2010||Launches H1N1 influenza vaccine (live) – Nasovac, liquid pentavalent vaccine in pre-filled syringes – Pentavac PFS, IPV Poliovac PFS, and r-EPO – Repoitin in pre-filled syringes|
|2008||Launches combi-pack of pentavalent vaccine – Pentavac and quadravalent vaccine, Quadrovax. It is recognized as India's No. 1 Bio-tech company for the 3rd consecutive year|
|2005||Launches indigenously developed DTP-HB combination vaccine – SII Q-VAC|
|2001||Launches indigenously manufactured Hepatitis-B vaccine (rDNA) – GeneVac-B|
|1993||Launches India's first MMR Vaccine – Tresivac|
Updated: March, 2014